Premium
Cost‐effectiveness of high‐dose chemotherapy in first‐line treatment of advanced multiple myeloma
Author(s) -
Sampson F. C.,
Beard S. M.,
Scott F.,
Vandenberghe E.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02854.x
Subject(s) - multiple myeloma , chemotherapy , medicine , autologous stem cell transplantation , cost effectiveness , oncology , first line treatment , intensive care medicine , risk analysis (engineering)
The cost‐effectiveness of high‐dose chemotherapy in multiple myeloma was considered as part of a UK National Health Service Executive regional evidence‐based appraisal process. The use of high‐dose chemotherapy supported by autologous stem cell transplantation in patients under 65 years of age was shown to provide a marginal benefit of 0·7 life‐years over conventional chemotherapy. This corresponded to an incremental cost ‘per life‐year gained’ figure of approximately £15 000, based upon initial treatment costs and trial‐period data only. The use of high‐dose chemotherapy in the first‐line treatment of advanced multiple myeloma improves event‐free and overall survival and appears to be a cost‐effective treatment option.